Epithelial ovarian cancer outcomes unrelated to extreme drug resistance
MedWire News: The survival outcomes of women with advanced epithelial ovarian, fallopian, and primary peritoneal cancers are not affected by extreme drug resistance (EDR) to multiple agents in vitro, conclude US scientists.
Koji Matsuo, from the University of Texas in Houston, and colleagues studied 253 cases of advanced ovarian, fallopian, and primary peritoneal cancers, evaluating in-vitro resistance to 13 drugs divided into platinum and taxane (primary group) versus other agents (secondary group).
Dual resistance, defined as at least one EDR in the primary and secondary treatment groups, was detected in 20.9 percent of patients, while 0.4 percent had complete EDR to all drugs tested, and 29.4 percent of cases showed no EDR.
Dual resistance was not associated with chemotherapy response or survival outcomes. There was no correlation between the number of drugs in the EDR range and chemotherapy response, progression-free survival, or overall survival.
The team writes: “This information is valuable with respect to the feedback given to the patient during counseling when the assay results reveal dual-resistance.”
They add: “Although correlating in-vitro and in-vivo drug resistance can be difficult , this interesting topic of drug resistance merits further investigation.”
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2009
By Liam Davenport